We are live on ! Find out more
FCMI

Foresite Capital Management II Portfolio holdings

AUM $29.2M
1-Year Est. Return 44.84%
This Fund
S&P 500
This Quarter Est. Return
-0.11%
1 Year Est. Return
+44.84%
3 Year Est. Return
-66.21%
5 Year Est. Return
-36.36%
10 Year Est. Return
–
AUM
$218M
AUM Growth
-$14.9M
Cap. Flow
-$5.63M
Cap. Flow %
-2.58%
Top 10 Hldgs %
99.53%
Holding
16
New
3
Increased
2
Reduced
6
Closed
3

Top Buys

Rank Stock Value
1
AERI
Aerie Pharmaceuticals
AERI
+$4.64M
2
ALDR
Alder Biopharmaceuticals
ALDR
+$1.62M
3
AKBA icon
Akebia Therapeutics
AKBA
+$634K
4
ARDX icon
Ardelyx
ARDX
+$318K
5
SGMO
SANGAMO THERAPEUTICS INC
SGMO
+$295K

Top Sells

Rank Stock Value
1
NSTG
NanoString Technologies, Inc.
NSTG
+$4.21M
2
NVET
Nexvet Biopharma plc Ordinary Shares
NVET
+$3.41M
3
DERM
Dermira, Inc.
DERM
+$1.52M
4
LRMR icon
Larimar Therapeutics
LRMR
+$1.41M
5
EPZM
Epizyme, Inc
EPZM
+$882K

Sector Composition

Rank Sector Weight
1 Healthcare 20.31%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AERI
1
DELISTED
Aerie Pharmaceuticals
AERI
$87.9M 40.27%
1,672,714
+99,688
+6% +$4.64M
AIMT
2
DELISTED
Aimmune Therapeutics
AIMT
$82.1M 37.61%
3,992,517
– –
EPZM
3
DELISTED
Epizyme, Inc
EPZM
$22.4M 10.27%
1,484,740
-58,378
-4% -$882K
ALDR
4
DELISTED
Alder Biopharmaceuticals
ALDR
$12M 5.48%
1,043,832
+87,791
+9% +$1.62M
NSTG
5
DELISTED
NanoString Technologies, Inc.
NSTG
$4.2M 1.92%
254,015
-238,524
-48% -$4.21M
DERM
6
DELISTED
Dermira, Inc.
DERM
$3.94M 1.81%
135,294
-50,000
-27% -$1.52M
OREX
7
DELISTED
Orexigen Therapeutics, Inc.
OREX
$1.75M 0.8%
602,013
-20,000
-3% -$60K
JNCE
8
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$1.68M 0.77%
119,912
– –
AKBA icon
9
Akebia Therapeutics
AKBA
$327M
$719K 0.33%
+50,000
New +$634K
BLCM
10
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$591K 0.27%
5,056
-5,444
-52% -$676K
LRMR icon
11
Larimar Therapeutics
LRMR
$416M
$420K 0.19%
9,975
-27,480
-73% -$1.41M
SGMO
12
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$405K 0.19%
+46,000
New +$295K
ARDX icon
13
Ardelyx
ARDX
$1.24B
$191K 0.09%
+37,500
New +$318K
NTRA icon
14
Natera
NTRA
$37.5B
– –
-50,737
Closed -$450K
XLRN
15
DELISTED
Acceleron Pharma
XLRN
– –
-19,910
Closed -$527K
NVET
16
DELISTED
Nexvet Biopharma plc Ordinary Shares
NVET
– –
-877,134
Closed -$3.41M

Similar funds

AG
Appleton Group Appleton, Wisconsin $28.6M AUM 32.21% 1-Year Est. Return
SAM
Sandbar Asset Management London, United Kingdom $30.5M AUM 46.07% 1-Year Est. Return
AC
Amia Capital London, United Kingdom $32.1M AUM 0.56% 1-Year Est. Return
QI
Qualcomm Inc San Diego, California $32.1M AUM 5.35% 1-Year Est. Return
TAAM
Top Ace Asset Management Hong Kong $25.3M AUM 23.27% 1-Year Est. Return
NAM
Nationwide Asset Management Columbus, Ohio $25.1M AUM 13.37% 1-Year Est. Return
MSKCC
Memorial Sloan Kettering Cancer Center New York $24.6M AUM 10.16% 1-Year Est. Return
BRC
Bishop Rock Capital New York $24.3M AUM 20.73% 1-Year Est. Return

Foresite Capital Management II's Q2 2017 Portfolio in Review

As of Q2 2017, Foresite Capital Management II held 16 positions worth $218M, down 6.4% from $233M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Foresite Capital Management II's Q2 2017 filing shows 3 new, 2 increased, 6 reduced and 3 closed positions. Its largest new stake was Akebia Therapeutics: 50,000 shares worth $719K. The largest sale was NanoString Technologies, Inc., an estimated $4.21M.

By sector, the portfolio is most concentrated in Healthcare at 20% of assets, down from 29% a quarter earlier.

  • Foresite Capital Management II's largest Q2 2017 buy was Akebia Therapeutics: 50,000 shares worth $719K.
  • Foresite Capital Management II added most to Aerie Pharmaceuticals in Q2 2017, an estimated $4.64M increase.
  • Foresite Capital Management II's biggest Q2 2017 reduction was NanoString Technologies, Inc., cutting an estimated $4.21M.
  • Foresite Capital Management II fully exited Nexvet Biopharma plc Ordinary Shares in Q2 2017, selling an estimated $3.41M.
  • Foresite Capital Management II's ten largest holdings make up 100% of its $218M portfolio in Q2 2017.
  • Foresite Capital Management II opened 3 new positions and closed 3 in Q2 2017.
  • Foresite Capital Management II's portfolio value fell 6.4% quarter-over-quarter to $218M.

Based on Foresite Capital Management II's 13F filing for Q2 2017, filed 14 Aug 2017.